Half Year 2023 Neuren Pharmaceuticals Ltd Earnings Call Transcript
Okay. Good morning, everyone. Thanks very much for taking the time to listen. I know it's a very busy time for everyone, and there's a lot of people who are listening in. So many thanks for that. As always, I have to just say that there's going to be some forward-looking statements in what I say and in some of the slides that -- subject to risks that could lead to different outcomes.
So I'm incredibly excited to be talking to you this morning after our first-half result. Not that there's any surprises in it, to be honest. It's the exact -- pretty much in line with what everyone was expecting. But I definitely think worth reflecting on what has been just an incredible six months for us, and I'll take a little bit of poetic license and add in the first two weeks of July, which, of course, takes in the spend at Acadia deal. This period has just been enormous for us.
And you know, often in biotech, it's not necessarily reflected in the financials, but in this case, it absolutely is, as you can see this morning. So we've declared a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
